At the same time, reduced telomerase activity, shortening telomeric length, activation of the DNA damage response related to ATM kinase, and increased expression of p21 and p27 can be observed in human leukemia cell line K562 under treatment with telomestatin [163]. This evidence concerns the gene CDKN1A and leukemia.